Want to see PETV full AI Analyst Report?
Top Page
PetVivo Holdings
(OTC:PETV)
Select Model
Select Model
Rating:46Neutral
Price Target:
$0.86
▼(-23.04% Downside)
Action:Reiterated
Date:06/30/26
The score is primarily held down by weak financial performance—large ongoing losses and persistent cash burn with a limited liquidity cushion—despite improved leverage. Offsetting this is a mixed-but-improving narrative from the earnings call around commercialization and regulatory milestones, while valuation is hard to justify with negative earnings and no dividend, and technical signals are unavailable, keeping the overall assessment cautious.
Positive Factors
Health Canada device recognition
Regulatory recognition by Health Canada creates a durable commercial beachhead in Canada, expanding addressable market exposure into a veterinary market growing ~6.8% CAGR. Device approval reduces regulatory friction for clinics and distributors, supporting multi-year sales growth and credibility among veterinary customers.
Negative Factors
Persistent cash burn
Consistent negative operating cash flow (~-$6.1M in 2026) is a structural financing challenge: it erodes runway, forces repeated capital raises, and constrains investments in sales, marketing, and R&D. Without sustained positive OCF, commercialization and product development timelines face recurring funding risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Health Canada device recognition
Regulatory recognition by Health Canada creates a durable commercial beachhead in Canada, expanding addressable market exposure into a veterinary market growing ~6.8% CAGR. Device approval reduces regulatory friction for clinics and distributors, supporting multi-year sales growth and credibility among veterinary customers.
Read all positive factors
PetVivo Holdings (PETV) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$31.58M
Dividend YieldN/A
Average Volume (3M)21.60K
Price to Earnings (P/E)―
Beta (1Y)0.06
Revenue Growth0.80%
EPS Growth9.08%
CountryUS
Employees20
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.40
Shares Outstanding37,594,246
10 Day Avg. Volume14,407
30 Day Avg. Volume21,604
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)9.60
Price to Sales (P/S)18.49
P/FCF Ratio-3.45
Enterprise Value/Market Cap0.67
Enterprise Value/Revenue19.07
Enterprise Value/Gross Profit28.88
Enterprise Value/Ebitda-2.69
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PetVivo Holdings Business Overview & Revenue Model
Company Description
PetVivo Holdings, Inc. operates as a biomedical technology firm, specializing in the invention, commercialization, and licensing of advanced medical devices and biomaterials intended to treat a variety of ailments and diseases affecting animals. I...
How the Company Makes Money
PetVivo makes money primarily by selling its veterinary medical device products, with revenue generated from commercial sales of its osteoarthritis/joint treatment product(s) (including SPRYNG™) into the companion-animal and equine markets. These ...
PetVivo Holdings Earnings Call Summary
Earnings Call Date:Jun 29, 2026
(Q4-2026)
| % Change Since: |
Next Earnings Date:Aug 06, 2026
Earnings Call Sentiment Neutral
The call conveyed a mix of meaningful strategic and technological progress (AI platform milestones, exclusive AI partnership, Health Canada device recognition, PBM acquisition, strong reductions in liabilities) alongside notable near-term financial challenges (small absolute revenues with only 1% growth, a material gross margin decline driven by low-margin PrecisePRP sales, a $1M impairment, and a $10.5M net loss and cash burn). Operational and product milestones provide a positive long-term narrative, but the company faces short-term execution, profitability, and liquidity risks that balance the positive developments.Positive Updates
Revenue Growth (Modest)
Total revenue increased 1% year-over-year to $1.14 million (FY2026). Distributor sales totaled $886,000 and direct clinic sales totaled $255,000.
Negative Updates
Gross Margin Decline
Gross profit decreased to $754,700 (66.1% of revenues) from $994,900 (87.8% of revenues) in the prior year — a drop of 21.7 percentage points in gross margin, driven primarily by low-margin PrecisePRP sales under the VetStem license.
Read all updates
Q4-2026 Updates
Positive
Negative
Revenue Growth (Modest)
Total revenue increased 1% year-over-year to $1.14 million (FY2026). Distributor sales totaled $886,000 and direct clinic sales totaled $255,000.
Read all positive updates
Company Guidance
The company guided to several near‑term commercial and clinical milestones: a PetVivo.ai B2B commercial launch expected within the next few months after beta refinement (PetVivo.ai has shown a 50%–90% reduction in veterinary customer acquisition costs, lowering typical CAC from $80–$400 to under $43, and targets very high 80%–90% gross margins), a Canadian Spryng rollout planned near the end of July following Health Canada recognition (Canada animal health market ~6.8% CAGR to >$4.4B by 2031), and completion of large animal studies with Powell Diazo and UConn around calendar year‑end to support future IDE filings; Digital Landia’s AgenticPet has demonstrated 97% diagnostic accuracy and onboarded >1,000 beta users in <72 hours. Management expects higher gross margins going forward (Spryng margins >90%), continued sales momentum into fiscal 2027, accelerated product pipeline expansion from the recently announced PBM acquisition (Stage C to confirm safety/efficacy), and many news catalysts over the next 12 months, all while having strengthened the balance sheet (current assets $1.8M, current liabilities $1.4M, total liabilities down 80%, working capital $482,600 after $877,500 net proceeds raised in the final quarter).PetVivo Holdings Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
44
Neutral
Cash Flow
16
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.11M | 1.14M | 1.13M | 968.71K | 917.16K | 115.59K |
| Gross Profit | 734.22K | 754.75K | 994.86K | 739.53K | 390.35K | -85.57K |
| EBITDA | -7.87M | -8.68M | -7.69M | -10.49M | -8.62M | -4.99M |
| Net Income | -9.93M | -10.47M | -8.40M | -10.96M | -8.70M | -4.94M |
Balance Sheet | ||||||
| Total Assets | 4.38M | 3.58M | 9.34M | 3.12M | 2.44M | 7.43M |
| Cash, Cash Equivalents and Short-Term Investments | 168.16K | 200.78K | 377.69K | 87.40K | 475.31K | 6.11M |
| Total Debt | 70.56K | 376.16K | 2.90M | 1.37M | 345.33K | 332.85K |
| Total Liabilities | 997.40K | 1.38M | 5.12M | 2.43M | 1.71M | 1.44M |
| Stockholders Equity | 3.38M | 2.20M | 4.22M | 685.95K | 725.02K | 5.99M |
Cash Flow | ||||||
| Free Cash Flow | -7.05M | -6.12M | -5.89M | -7.73M | -7.22M | -4.36M |
| Operating Cash Flow | -6.52M | -6.11M | -5.32M | -7.42M | -6.79M | -4.17M |
| Investing Cash Flow | -509.40K | 11.80K | -563.43K | -309.10K | -423.93K | -183.18K |
| Financing Cash Flow | 7.02M | 6.07M | 6.03M | 7.34M | 1.59M | 10.44M |
PetVivo Holdings Technical Analysis
Positive
1.12
Price Trends
0.79
Positive
0.77
Positive
0.96
Negative
Market Momentum
0.02
Negative
54.80
Neutral
73.08
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PETV, the sentiment is Positive. The current price of 1.12 is above the 20-day moving average (MA) of 0.80, above the 50-day MA of 0.79, and above the 200-day MA of 0.96, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 54.80 is Neutral, neither overbought nor oversold. The STOCH value of 73.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PETV.
PetVivo Holdings Risk Analysis
PetVivo Holdings disclosed 35 risk factors in its most recent earnings report. PetVivo Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
PetVivo Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $31.58M | -2.13 | -256.06% | ― | 0.80% | 9.08% | |
45 Neutral | $20.37M | -6.16 | -148.64% | ― | 7.73% | 55.39% | |
44 Neutral | $21.64M | -0.39 | -127.95% | ― | -17.67% | 46.19% | |
43 Neutral | $6.92M | -0.22 | -335.47% | ― | 33.77% | -20.22% |
* Healthcare Sector Average
PETV
PetVivo Holdings
0.84
0.06
7.69%
IRIX
Iridex
1.17
0.26
28.57%
LFWD
Lifeward
7.69
-0.38
-4.73%
VVOS
Vivos Therapeutics
0.50
-3.33
-87.00%
NXL
Nexalin Technology, Inc.
0.38
-0.60
-61.22%
PetVivo Holdings Corporate Events
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
PetVivo to Acquire PiezoBioMembrane, Expanding Biomaterials Platform
Positive
Jun 25, 2026
On June 24, 2026, PetVivo Holdings, Inc., a provider of medical devices and biomedical therapeutics for equines and companion animals, announced an agreement to acquire PiezoBioMembrane, Inc., a developer of advanced functional biomaterials and pi...
Private Placements and Financing
PetVivo Holdings Raises Additional Capital via Private Placement
Positive
Jun 11, 2026
On June 8, 2026, PetVivo Holdings, Inc. received $150,000 in gross proceeds from a partial exercise of an investor purchase option under a March 13, 2026 subscription agreement, bringing total equity raised in this offering to $1,150,000 and total...
Private Placements and Financing
PetVivo Completes Private Equity Financing and Raises Capital
Positive
Apr 17, 2026
On April 15, 2026, PetVivo Holdings, Inc. received the final $600,000 installment under a March 13, 2026 subscription agreement, completing a $1,000,000 private equity financing. The company issued a total of 1,250,000 units at $0.80 per unit, eac...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.